A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 After Administration of Multiple Ascending Doses for 8 Days in Healthy Male or Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs AZD 5069 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 27 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Apr 2010 Actual patient number (8) added as reported by ClinicalTrials.gov.
- 09 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.